title: Patient Perceived Benefit in Facial Aesthetic Procedures: FACE-Q as a Tool to Study Botulinum Toxin Injection Outcomes.
abstract: BACKGROUND
  There are numerous methods of assessing patient satisfaction with botulinum toxin type A neuromodulation of the glabellar rhytids. As the use of aesthetic neuromodulation increases both in breadth and number of procedures, there is a need for more comprehensive tools to evaluate patient-reported outcomes. The FACE-Q is a recently validated patient-reported outcome instrument that can be used to measure patient perceptions of botulinum toxin type A neuromodulation.
  
  
  OBJECTIVE
  This study used the FACE-Q to assess patient satisfaction following botulinum toxin type A neuromodulation of the glabellar rhytids.
  
  
  METHODS
  57 female patients completed the FACE-Q, a survey that evaluates patients' satisfaction with their facial appearance. After this baseline survey, the patients received injections of one of onabotulinumtoxinA (Botox, Allergan, Dublin, Ireland), abobotulinumtoxinA (Dysport, Galderma, Lausanne, Switzerland), or incobotulinumtoxinA (Xeomin, Merz Pharmaceuticals, Frankfurt am Main, Germany) in the glabella. Two weeks post-injection, the patients completed the FACE-Q again. The percentage changes in patient responses were tabulated to determine how neuromodulation affects patient satisfaction with their facial appearance. The percentage changes for each of the neurotoxin groups were compared to determine if patient satisfaction with neuromodulation varies with the type of neurotoxin.
  
  
  RESULTS
  Patient satisfaction with their overall facial appearance increased by 28% following neuromodulation. Patients stated that they believe they look an average of 5.6 years younger post-neuromodulation. There were no significant differences among the treatment groups.
  
  
  CONCLUSIONS
  The FACE-Q demonstrates that patients are more satisfied by their overall facial appearance and age appearance following neuromodulation of their glabellar rhytids. Patients are equally satisfied with the improvement of their facial appearance regardless of which neurotoxin they received. LEVEL OF EVIDENCE 2: Therapeutic.
authors.affiliation: From the Division of Plastic Surgery, University of Pennsylvania, Philadelphia, PA.
authors.forename: Brian L
authors.initials: BL
authors.lastname: Chang
authors.affiliation: From the Division of Plastic Surgery, University of Pennsylvania, Philadelphia, PA.
authors.forename: Anthony J
authors.initials: AJ
authors.lastname: Wilson
authors.affiliation: From the Division of Plastic Surgery, University of Pennsylvania, Philadelphia, PA.
authors.forename: Anthony J
authors.initials: AJ
authors.lastname: Taglienti
authors.affiliation: From the Division of Plastic Surgery, University of Pennsylvania, Philadelphia, PA.
authors.forename: Catherine S
authors.initials: CS
authors.lastname: Chang
authors.affiliation: From the Division of Plastic Surgery, University of Pennsylvania, Philadelphia, PA.
authors.forename: Nancy
authors.initials: N
authors.lastname: Folsom
authors.affiliation: From the Division of Plastic Surgery, University of Pennsylvania, Philadelphia, PA.
authors.forename: Ivona
authors.initials: I
authors.lastname: Percec
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D019274:Botulinum Toxins, Type A / Q000627:therapeutic use*; D003357:Cosmetic Techniques / Q000523:psychology*; D004954:Esthetics / Q000523:psychology*; D005145:Face; D005260:Female; D006801:Humans; D008875:Middle Aged; D009498:Neurotoxins / Q000627:therapeutic use*; D017060:Patient Satisfaction; D015595:Skin Aging / Q000187:drug effects*; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D009498:Neurotoxins; D019274:Botulinum Toxins, Type A